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was completely inhibited. Under the same experimental condi- 
tions, changes in the total release of G2 domain measured by the 
G2 assay showed a different profile. There was an initial increase 
between days 2 and 5 followed by a progressive decline reaching 
detection limit by day 12 (Fig. 1 ). The addition of GM6001 did not 
have any influence on the course of this curve. 
Conclusion: These results suggest that the herein introduced 
sandwich immuno-assays G2 and FFGVG-G2 allow the assess- 
ment of separate processes of aggrecan metabolism in articular 
cartilage. Whereas the monitoring of FFGVG-G2 reflect aggrecan 
degradation, further studies are needed to clarify which aspects 
of aggrecan turnover are reflected by the changes in the total re- 
lease of the G2 domain from the explant cultures. The herein pre- 
sented assays carry noteworthy potentials to become useful tools 
for monitoring disease processes and the effects of interventions. 
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While a homeostatic balance between matrix synthesis and 
degradation is maintained in healthy cartilage, metabolic pro- 
cesses are modulated in osteoarthritis to favor catabolism. In this 
study, a novel biochemical method for measuring aspects of cell 
and matrix turnover using a single stable isotope precursor was 
validated and used to profile metabolic changes in animal and 
tissue culture models of cartilage degeneration. 
Bovine cartilage explants were maintained with medium including 
I L-1. For in vivo studies, degeneration was induced in rat knees by 
either chemical (monoiodoacetate) or mechanical (meniscal tear) 
interventions. Cartilage degeneration was confirmed by quantify- 
ing the release of sulfated GAG into culture medium or by his- 
tological analysis. To label newly-synthesized metabolites, 2H20 
was administered via either culture medium or drinking water. 
After isolation of DNA and chondroitin sulfate (CS) from carti- 
lage samples, the 2 H enrichments were quantified by GC/MS and 
used to calculate fractional de novo synthesis. 
Cartilage explants analyzed after 5 days in serum-supplemented 
culture had fractional CS synthesis of 134-2% (2.64-0.4%/day; 
n=4). This was comparable to the rate at which GAG was re- 
leased into the medium (2.3%/day). The inclusion of IL-1 inhibited 
the rate of CS turnover dose-dependently (Fig. 1A). Chondrocyte 
turnover (1.14-0.5%/day; n=16) also was inhibited by IL-1 (Fig. 
1B). 
MIA-treated rat knees developed regions of cartilage matrix loss 
and decreased cell viability 5 days after injection, and the de- 
generation progressively worsened. However, CS turnover in the 
cartilage from the affected knee remained indistinguishable from 
control knees until 9 days post-injection (Fig. 2). Rat knees in 
which the medial meniscus was torn exhibited gross degenera- 
tive changes earlier, within 3 days of surgery. CS synthesis was 
elevated with the onset of cartilage degeneration (day 3) relative 
to control knees, returning to control levels by day 9 (Fig. 3). In 
both forms of experimental OA, the degenerating cartilage exhib- 
ited a period of marked stimulation in CS turnover (~2X of con- 
trol), but this increase occurred on different timecourses. While 
the physiological implication of this is as yet unclear, it is evident 
that changes in CS synthesis rates are detectable in vivo and are 
modulated in both physical and chemical models of OA. 
This stable isotope/mass pectrometry approach can be used to 
measure turnover of other matrix constituents. Preliminary mea- 
surements indicate that in normal rat cartilage, collagen turns 
over at a rate of 1-3%/day. Thus, the method is robust, allowing 
multiple, simultaneous measurements from a single specimen of 
cartilage. The ability to evaluate cell-mediated alterations during 
OA progression in vitroand in vivois appealing in small animal ex- 
perimentation but may also have significant clinical applications. 
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Introduction: Helix-II and CTX-II are type II collagen degradation 
markers recognizing specific sequences from the helical and C- 
telopeptide domains of type II collagen, respectively. Both mak- 
ers are elevated in urine of patients with osteoarthritis (OA) or 
rheumatoid arthritis (RA). However, in these clinical conditions, 
Helix-II and CTX-II correlate only moderately with each other, 
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